— Shanghai Children's Hospital and InnovaRadi Sign Strategic Collaboration Agreement to Advance Clinical Research and Translation of Innovative Targeted Radiopharmaceuticals for Pediatric Solid Tumors

2026-03-10

Recently, with the strong support and facilitation of Academy for Clinical Innovation & Translation of Shanghai (hereinafter referred to as “ACITS”), Shanghai Children’s Hospital and Shanghai InnovaRadi Biotech Co., Ltd. (hereinafter referred to as “InnovaRadi”) officially signed a strategic collaboration agreement. The two parties will conduct in-depth collaboration in the field of novel radionuclide therapies for pediatric malignant solid tumors, jointly promoting the research, development, and clinical translation of innovative targeted radiopharmaceuticals to improve the diagnosis and treatment of pediatric solid tumors.

This collaboration has received full support and facilitation from ACITS throughout the entire process. From the early stage of the project, ACITS effectively aligned the needs of both parties and provided critical support for building the collaboration framework and integrating resources. In the future, ACITS will continue to support the project by optimizing clinical research and coordinating relevant resources, helping to establish an innovative and replicated collaboration model.

Shanghai Children’s Hospital is a National Class A Tertiary Hospital in China, with strong capabilities and extensive experience in the clinical treatment of major pediatric diseases, scientific innovation, and medical translation. Recently, it obtained the Radiation Safety License for the α-emitting radionuclide astatine-211 (²¹¹At), becoming the first medical institution in Shanghai to receive such a license. It is also the first pediatric specialty hospital in China to systematically establish a research and development framework for radionuclide therapy targeting pediatric malignant tumors.

InnovaRadi has long been dedicated to the development of novel radionuclide therapies for pediatric malignant solid tumors and has established a proprietary technology platform with integrated capabilities spanning research and clinical translation. Leveraging the complementary strengths of both parties in clinical resources and innovative technologies, this collaboration is expected to further promote synergistic innovation in advanced radionuclide therapies for pediatric oncology.

Under the principles of “complementary advantages, collaborative innovation, and mutual development,” the two parties will establish a long-term, stable, and mutually trusted strategic partnership. Together, they will build an internationally leading platform for the research and clinical translation of innovative targeted radiopharmaceuticals for pediatric solid tumors. The collaboration aims to continuously generate innovative outcomes and accelerate the translation of novel targeted radiopharmaceuticals from basic research to clinical application, exploring more precise and effective treatment strategies for pediatric tumors. This initiative will help raise the standards of diagnosis and treatment for pediatric malignant solid tumors in China to an internationally advanced level, while providing more accessible and sustainable innovative treatment options for pediatric patients.